Share
406 Posts.
lightbulb Created with Sketch. 16
clock Created with Sketch. 24/11/15
16:30
Share
Originally posted by dolcevita
↑
Great post nikki.insulation from hostile takeover with so many shares in the CEO and other executive hands. That and Thorney which is a white knight with family/friend connections. There are others for sure but MSB is uniquely placed on this front. It's one of the first risks I look at with a bio.insufficient capital to take a sound innovation to market. The research stage is by far the cheapest, development and commercialisation (including FDA trials) is the killer. The deal with Cephalon/Teva backed MSB for at least one application. For a long while it looked like that would expand into other applications, but we are now engaged in discussions with Big Pharma, Celgene, and others for that. For a long time madamswer made a big deal over uncertainty of funding. He was right that Teva haven't backed the rest of the trials (as I'd anticipated) but that doesn't make MSB a wallflower at a dance. Plenty of suitors around. But no perspective on that.
Expand
J
(20min delay)